Search

Your search keyword '"Adriana Forti"' showing total 18 results
Start Over Author "Adriana Forti"
18 results on '"Adriana Forti"'

1. Relevance of Target-Organ Lesions as Predictors of Mortality in Patients with Diabetes Mellitus

Author

Henrique Tria Bianco, Maria Cristina Izar, Henrique Andrade Fonseca, Rui Manuel Póvoa, José Francisco Saraiva, Adriana Forti, Paulo Cesar B. V. Jardim, Luis Introcaso, Juan Yugar-Toledo, Hermes Tóros Xavier, André Arpad Faludi, and Francisco A. H. Fonseca

Subjects
Diabetes Mellitus Tipo 2 / mortalidade, Epidemiologia, Diabetes Mellitus Tipo 2 / complicações, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Background: Patients with diabetes are in extract higher risk for fatal cardiovascular events. Objective: To evaluate major predictors of mortality in subjects with type 2 diabetes. Methods: A cohort of 323 individuals with type 2 diabetes from several regions of Brazil was followed for a long period. Baseline electrocardiograms, clinical and laboratory data obtained were used to determine hazard ratios (HR) and confidence interval (CI) related to cardiovascular and total mortality. Results: After 9.2 years of follow-up (median), 33 subjects died (17 from cardiovascular causes). Cardiovascular mortality was associated with male gender; smoking; prior myocardial infarction; long QTc interval; left ventricular hypertrophy; and eGFR

Published
2014
Full Text
View/download PDF

2. Hyperglycemia in pregnancy: sleep alterations, comorbidities and pharmacotherapy

Author

Cristina Façanha, Veralice de Bruin, Pedro de Bruin, Arthur Façanha, Hellen Cristina Rocha, Mariana Araujo, Adriana Forti, and Rejane Macêdo

Subjects
Sleep Wake Disorders, Diabetes mellitus. Sleep. Pregnancy in diabetics. Diabetes, Medicine (General), medicine.medical_specialty, endocrine system diseases, Excessive daytime sleepiness, Disorders of Excessive Somnolence, 030204 cardiovascular system & hematology, Pittsburgh Sleep Quality Index, 03 medical and health sciences, R5-920, 0302 clinical medicine, Pregnancy, Internal medicine, Diabetes mellitus, medicine, Humans, 030212 general & internal medicine, Type 1 diabetes, business.industry, Epworth Sleepiness Scale, Type 2 Diabetes Mellitus, General Medicine, medicine.disease, Sleep in non-human animals, Gestational diabetes, Diabetes, Gestational, Diabetes Mellitus, Type 2, Hyperglycemia, gestational. Sleepiness, Female, medicine.symptom, Sleep, business
Abstract

SUMMARY OBJECTIVE: To investigate sleep alterations and associated factors in pregnant diabetic women (n=141). METHODS: Sleep profile, sociodemographics and clinical information were collected. Poor sleep quality (Pittsburgh Sleep Quality Index >5) and excessive daytime sleepiness (Epworth Sleepiness Scale ≥10), sleep duration (h), sleep latency (min), frequent sleep interruption and short sleep (≤6 h) were assessed in type 1 diabetes mellitus (16.3%), type 2 diabetes mellitus (25.5%) and gestational diabetes mellitus (58.2%). RESULTS: Poor sleep quality was found in 58.8% of patients and daytime sleepiness in 25.7%, regardless of hyperglycemia etiology. No correlation existed between daytime sleepiness and poor sleep quality (Pearson correlation r=0.02, p=0.84). Short sleep duration occurred in 1/3 of patients (31.2%). Sleep interruptions due to frequent urination affected 72% of all and sleep interruptions due to any cause 71.2%. Metformin was used by 65.7% of type 2 diabetes mellitus and 28.7% of gestational diabetes mellitus. In gestational diabetes mellitus, parity number was independently associated with poor sleep quality (p=0.02; OR=1.90; 95%CI 1.07-3.36) and metformin use was also independently associated with poor sleep quality (p=0.03; OR=2.36; 95%CI 1.05-5.29). CONCLUSIONS: Our study originally shows that poor sleep quality and excessive daytime sleepiness are frequent in diabetic pregnancy due to different etiologies. Interestingly, only in gestational diabetes mellitus, metformin therapy and higher parity were associated with poor sleep quality.

Published
2021

3. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

Author

Ruilope, Luis M, Agarwal, Rajiv, Anker, Stefan D, Bakris, George L, Filippatos, Gerasimos, Nowack, Christina, Kolkhof, Peter, Joseph, Amer, Mentenich, Nicole, Pitt, Bertram, Diego, Besada, Alfredo, Wassermann, Julio, Bittar, Alicia, Elbert, Augusto, Vallejos, Gloria, Viñes, Hugo, Sanabria, Federico Pérez Manghi, Alberto, Liberman, Inés, Bartolacci, Diego, Aizenberg, Mariano, Chahin, Laura, Maffei, Elizabeth, Gelersztein, Bernhard, Ludvik, Hans-Robert, Schönherr, Heinz, Drexel, Wolfgang, Preiß, Ursula, Hanusch, Peter, Neudorfer, Friedrich, Prischl, Bernhard, Paulweber, Christoph, Ebenbichler, Rudolf, Prager, Harald, Sourij, Gerit-Holger, Schernthaner, Martin, Clodi, Evelyn, Fliesser-Görzer, Elif, Ekinci, Richard, Macisaac, David, Packham, Hugo, Stephenson, Michael, Suranyi, Gary, Wittert, Katie-Jane, Wynne, Alexia, Pape, Duncan, Topliss, Peter, Colman, Craig, Nelson, James, Vandeleur, David, Colquhoun, Simon, Roger, Peak Mann Mah, Walter, Abhayaratna, Luc VAN Gaal, Pieter, Gillard, Jean-Michel, Hougardy, Marijn, Speeckaert, Koen, Stas, Wendy, Engelen, Francis, Duyck, André, Scheen, Hilde, Vanbelleghem, Peter, Doubel, Svetla, Vasileva, Rosen, Rashkov, Boyan, Nonchev, Theodora, Temelkova-Kurktschieva, Mariana, Yoncheva-Mihaylova, Rangel, Rangelov, Neli, Klyuchkova, Pavel, Stanchev, Zhivko, Tagarev, Radostina, Boshnyashka, Petya, Manova, Zhulieta, Prakova, Mariya, Lucheva, Valentina, Gushterova, Ghassan, Farah, Dimitar, Georgiev, Mariyana, Pichmanova, Dotska, Minkova, Bilyana, Stoyanovska-Elencheva, Maria Eugenia Canziani, Miguel, Hissa, Irene, Noronha, Joao Eduardo Salles, Daniela, Antunes, Freddy, Eliaschewitz, Carlos Eduardo Figueiredo, Rogerio de Paula, Luis, Canani, Maurilo Leite Jr, Bruno, Paolino, Rosangela, Rea, Sergio, Vencio, Claudia, Brito, Raphael, Paschoalin, Roberto Pecoits Filho, Eduardo, Vasconcellos, Nathalia, Paschoalin, Adriana, Forti, Roberto, Botelho, Miguel, Riella, Dalton, Precoma, Maria, Cerqueira, Lilia, Maia, Evandro, Portes, Marcio, Pereira, Joanne, Liutkus, Dennis, O Keefe, Richard, Tytus, Brian, Carlson, James, Conway, Michael, Walsh, Igor, Wilderman, Andrew, Steele, Sheldon, Tobe, Louise, Vitou, Karthik, Tennankore, Valdemar, Martinho, Philip, Mcfarlane, Daniel, Shu, Serge, Cournoyer, Richard, Dumas, Giuseppe, Mazza, Guy, Tellier, George, Tsoukas, Stanley, Weisnagel, Jean-Francois, Yale, Sameh, Fikry, Randolph, Hart, Pavel, Hamet, Francois, Madore, Paul, Barre, Daniel, Schwartz, Allan, Kelly, Ivor, Teitelbaum, Sean, Peterson, Sam, Henein, Richard, Goluch, Gregoire, Wuerzner, Markus, Laimer, Stefan, Bilz, Marc, Donath, Gottfried, Rudofsky, Christopher, Strey, Antoinette, Pechère-Bertschi, Paola, Varleta, Fernando, González, Marcelo, Medina, Carmen, Romero, Victor, Saavedra, Juan Carlos Prieto, Eliana, Reyes, Juan Carlos Palma, Jorge, Cobos, Zhihong, Liu, Dalong, Zhu, Nan, Chen, Fang, Liu, Wang, Li, Qing, Su, Bingyin, Shi, Aiping, Yin, Hao, Wang, Yan, Li, Jianying, Niu, Chaoqing, Wu, Xinjun, Wang, Ying, Zhang, Peng, Ai, Jianhua, Ma, Yuxiu, Li, Hongguang, Zheng, Minxiang, Lei, Zhaohui, Mo, Nanwei, Tong, Jinluo, Cheng, Youping, Dong, Xudong, Xu, Qinkai, Chen, Tianjun, Guan, Gang, Long, Changying, Xing, Ling, Li, Yinghong, Liu, Hao, Zhang, Ling, Zhong, Zhonghe, Li, Longyi, Zeng, Jiali, Wei, Hanqing, Cai, Tianfeng, Wu, Weiping, Lu, Ning, Xu, Yibing, Lu, Dejun, Chen, Ruifang, Bu, Jiansong, Shen, Junwu, Dong, Zhiquan, Zhao, Fei, Xiong, Fangfang, Jiang, Jinkui, Yang, Jian, Kuang, Guoyuan, Lu, Lihua, Wang, Yanlin, Zhang, Shuifu, Tang, Weiying, Guo, Jian, Liu, Sheng, Jiang, Fang, Yi, Yuming, Du, Zhuxing, Sun, Yuantao, Liu, Liyong, Zhong, Dongmei, Li, Hongmei, Li, Chuanming, Hao, Feixia, Shen, Jianqin, Wang, Jingmei, Li, Dora, Molina, Carlos, Cure, Jaime, Ibarra, Gustavo, Aroca, Hernán, Yupanqui, Eric, Hernández, Mónica, López, Gregorio, Sánchez, Germán, Barreto, Edgar, Arcos, Miguel, Urina, William, Kattah, Carlos, Durán, Clara, Arango, Julian, Coronel, Guillermo, Blanco, Mónica, Terront, Gustavo, Guzmán, Luis, García, Carlos, Jaramillo, Manuel, Liévano, Diego, Benitez, Tatiana, Cárdenas, Iván, Villegas, Sandra, Barrera, Nicolás, Jaramillo, Rodrigo, Botero, Nelly Beltrán López, Freddy, Trujillo, Martin, Prazny, Jitka Hasalova Zapletalova, Libor, Okenka, Dino, Alferi, Tomas, Edelsberger, Pavel, Tomanek, Jiri, Brezina, Olga, Hola, Jana, Houdova, Petr, Bucek, David, Karasek, Sarka, Kopecka, Richard, Kovar, Michal, Brada, Lucie, Hornova, Eva, Krcova, Hana, Lubanda, Vlasta, Kutejova, Jiri, Kuchar, Helena, Hrmova, Jiri, Pumprla, Magdalena, Mokrejsova, Drahomira, Gulakova, Ivo, Matyasek, Thilo, Krüger, Hermann, Haller, Thorsten, Koch, Ludger, Rose, Diethelm, Tschöpe, Lutz, Stemler, Volker, Schettler, Andreas, Pfützner, Karl, Derwahl, Thomas, Horacek, Helena, Sigal, Heidrun, Täschner, Ingolf, Schiefke, Andreas, Hagenow, Andreas, Birkenfeld, Christoph, Axthelm, Christoph, Wanner, Klaus, Busch, Heike, Schlichthaar, Christoph, Hasslacher, Stefan, Degenhardt, Markus van der Giet, Georg, Strack, Norbert, Schöll, Bernhard, R Winkelmann, Lars, Rump, Ruth, Nischik, Bernd, Schröppel, Thomas, Giebel, Achim, Ulmer, Andrea, Rinke, Christel, Contzen, Wolfgang, Jungmair, Nicole, Toursarkissian, Christof, Kloos, Joachim, Müller, Thomas, Schürholz, Hermann, Braun, Frank, Pistrosch, Per, Poulsen, Claus, Juhl, Joan, Nielsen, Jesper, Bech, Ole, Rasmussen, Peter, Rossing, Jens, Faber, Thure, Krarup, Morten, Lindhardt, Ulrik Pedersen-Bjergaard Pedersen-Bjergaard, Karoline, Schousboe, Jørgen, Hangaard, Sten, Madsbad, Gunnar, Gislason, Grzegorz Jaroslaw Pacyk, Olga González Albarrán, Carlos Sánchez Juan, José Julián Segura de la Morena, Secundino Cigarrán Guldris, Francisco Martínez Deben, José María Pascual Izuel, Julio Pascual Santos, Francesca, Calero, Alfonso, Soto, Manuel Polaina Rusillo, Josep, Redón, Josep, Galcerán, Juan, Mediavilla, Mª Dolores Martínez Esteban, Alfredo, Michán, Fernando de Álvaro, Javier Escalada San Martín, Josep Cruzado Garrit, Cristina, Castro, Fernando Cereto Castro, Rafael Santamaría Olmo, Esteban, Poch, Judith, Martins, Julio Hernández Jaras, Meritxell, Ibernón, Daniel, Seron, Hanane, Bouarich, Maribel, Troya, Jorma, Strand, Ilkka, Kantola, Sakari, Nieminen, Arvo, Koistinen, Kristiina, Kananen, Sakari, Sulosaari, Mikko, Honkasalo, Pirkko, Korsoff, Tuomo, Nieminen, Karita, Sadeharju, Kari, Humaloja, Jorma, Lahtela, Philippe, Zaoui, Jean-Pierre, Fauvel, Ronan, Roussel, Didier, Gouet, Pierre, Serusclat, Sylvaine, Clavel, Bruno, Guerci, Bruno, Verges, Olivier, Moranne, Arnaud, Monier, Alexandre, Klein, François, Chantrel, Yannick LE Meur, Rafik, Mesbah, Bertrand, Cariou, Dominique, Guerrot, Karim, Gallouj, Kieran, Mccafferty, Arutchelvam, Vijayaraman, Yuk-Ki, Wong, Dhanya, Kalathil, Sam, Rice, Sui Phi Kon, Hassan, Kahal, Cuong, Dang, Fahmy, Hanna, Christina, Kyriakidou, Imrozia, Arif, Anne, Kilvert, Pauline, Swift, Ioannis, Stefanidis, Ploumis, Passadakis, Aikaterini, Papagianni, Erifili, Hatziagelaki, Dorothea, Papadopoulou, Ioannis, Boletis, Ioanna, Makriniotou, Theodora, Kounadi, Ioannis, Ioannidis, Paul, Lee, Ching Wan Ronald Ma, Vincent, Yeung, Tai Pang Ip, Ebrahim, Noori, Julianna, Kiss, Eleonora, Harcsa, Albert, Szocs, Szilard, Vasas, Krisztina, Wudi, Robert, Kirschner, Dora, Bajcsi, Beata, Lamboy, Botond, Literati-Nagy, Gabor, Nyirati, Gizella, Petro, Karoly, Schneider, Katalin, Keltai, Akos, Kalina, Peter, Danos, Szilvia, Kazup, Zsolt, Zilahi, Judit, Simon, Laszlo, Kovacs, Marianna, Zsom, Margit, Mileder, Laszlo, Nagy, Yoram, Yagil, Julio, Wainstein, Ofri, Mosenzon, Rosane Abramof Ness, Sydney Ben Chetrit, Faiad, Adawi, Idit, Liberty, Ehud, Grossman, Mazen, Elias, Zaher, Armaly, Evgeny, Farber, Assy, Nimer, Amir, Bashkin, Gil, Chernin, Shai, Efrati, Doron, Schwartz, Noa Berar Yanay, Mariela, Glandt, Robert, Zukermann, Majdi, Halabi, Shaul, Atar, Mahmud, Darawsha, Norberto, Perico, Gaetano La Manna, Giovanni Giorgio Battaglia, Domenico, Santoro, Piermarco, Piatti, Bonora, Enzo, Davide Carlo Maggi, Paolo, Calabrò, Roberto, Cimino, Roberto, Trevisan, Paolo, Fiorina, Antonio, Pisani, Antonello, Pani, Gennaro, Santorelli, Carlo Antonio Bossi, Giancarlo, Tonolo, Enrico, Fiaccadori, Anna Maria Veronelli, Michele, Emdin, Paola, Ponzani, Maria Cristina Gregorini, Franco Luigi Cavalot, Carlo Bruno Giorda, Taro, Shibasaki, Akihiro, Hamasaki, Takashi, Nomiyama, Sunao, Matsubayashi, Junji, Shinoda, Kazunari, Matsumoto, Hideo, Kanehara, Yoshihide, Hirohata, Masayo, Yamada, Jun, Nakazawa, Yoshimitsu, Yamasaki, Mikihiro, Nakayama, Ryuichi, Furuya, Osamu, Ebisui, Satsuki, Kawasaki, Daishiro, Yamada, Masayuki, Noritake, Tamayo, Ishiko, Nobuhiro, Sasaki, Daisuke, Suzuki, Asami, Tanaka, Miyuki, Kubota, Hideo, Araki, Hiroshi, Ohashi, Takeshi, Osonoi, Kazuo, Yamagata, Naruhiro, Fujita, Daisuke, Kanda, Seiichi, Tanaka, Junko, Koide, Masao, Ishii, Takayuki, Ogiwara, Masaaki, Suzuki, Taiji, Sekigami, Takayuki, Higashi, Yuko, Yambe, Yoshiro, Kusano, Hidetoshi, Kikuchi, Hiroaki, Miyaoka, Kiyoe, Kato, Masayuki, Kashima, Fumiko, Yamakawa, Shuji, Horinouchi, Hirofumi, Imoto, Hiroshi, Sobajima, Hidetoshi, Kanai, Naoki, Matsuoka, Hirotaka, Shibata, Akemi, Inagaki, Toshiyuki, Sugiura, Toru, Sugiyama, Hidekatsu, Yanai, Yoshiyuki, Hamamoto, Masahiro, Hatazaki, Terumasa, Hayashi, Kunihisa, Kobayashi, Satoshi, Murao, Makoto, Ujihara, Kazuya, Sugitatsu, Katsunori, Kawamitsu, Ken, Yamakawa, Izumi, Tsunematsu, Fumi, Kikuchi, Hideaki, Jinnouchi, Tetsuyuki, Yasuda, Hajime, Maeda, Yasuto, Matsuo, Hideki, Okamoto, Takeshi, Katsuki, Ken, Yajima, Takeshi, Morita, Masayuki, Inagaki, Wooje, Lee, Jungoo, Kang, Cheol Young Park, Hyesoon, Kim, Singon, Kim, Youcheol, Hwang, Injoo, Kim, Jaehyeon, Kim, Young Min Cho, Byungwan, Lee, Choonhee, Chung, Soo, Lim, Jae Myung Yu, Dovile, Kriauciuniene, Antanas, Navickas, Audrone, Velaviciene, Egle, Urbanaviciene, Gediminas, Urbonas, Jurate, Lasiene, Lina, Radzeviciene, Ron, Gansevoort, Adriaan, Kooy, G Lieverse, A, L Penne, E, Ruud J, M van Leendert, M van Buren, H Boonstra, A, C Bakker, R, Marielle, Krekels, B Brouwer, C, T Luik, P, J N, M Barendregt, Bert-Jan van den Born, Trine, Finnes, Thomas, Karlsson, Hilde, Selsås, Emil, Asprusten, Robert, Hagemeier, Erik, Eriksen, Knut, Risberg, Hans, Høivik, Leidulv, Solnør, Frode, Thorup, Jan, Rocke, Rick, Cutfield, Peter, Dunn, Jeremy, Krebs, Russell, Scott, Kingsley, Nirmalaraj, Nine, Smuts, John, Baker, Veronica, Crawford, Albert, Bautista, Roberto, Mirasol, Elizabeth, Catindig, Glenda, Pamugas, Louie, Tirador, Maribel, Tanque, Janusz, Gumprecht, Piotr, Napora, Edward, Franek, Andrzej, Stankiewicz, Katarzyna, Landa, Agnieszka, Tiuryn-Petrulewicz, Kazimierz, Ciechanowski, Bogna, Wierusz-Wysocka, Barbara, Rewerska, Grazyna, Cieslik, Michal, Hoffmann, Michal, Nowicki, Jolanta, Krzykowska, Stanislaw, Mazur, Katarzyna, Wasilewska, Anna, Ocicka-Kozakiewicz, Ewa, Skokowska, Renata, Wnetrzak-Michalska, Jan, Ruxer, Patrycja, Butrymowicz, Katarzyna, Madziarska, Ilona, Kurnatowska, Teresa, Rusicka, Adam, Madrzejewski, Tomasz, Stompor, Jose, Guia, Amalia, Pereira, Pedro, Melo, Cristina, Roque, Francisco, Rosario, Fernando Teixeira, E Costa, Fernando, Nolasco, Edgar, Almeida, Pedro, Matos, Cesar, Esteves, Rui, Carvalho, Ilidio, Brandao, Susana, Heitor, Ana Vila Lobos, Rosa, Ballesteros, Gil, Silva, Carlos, Barreto, Ana, Silva, Natalya, Vorokhobina, Alexander, Sherenkov, Ivan, Gordeev, Olga, Semenova, Sergey, Levashov, Vyacheslav, Marasaev, Ruslan, Sardinov, Vadim, Klimontov, Vitaliy, Baranov, Nadezhda, Verlan, Albert, Galyavich, Arkadiy, Demko, Zhanna, Kobalava, Elena, Zakharova, Lyudmila, Kvitkova, Oleg, Solovev, Elena, Smolyarchuk, Larisa, Zhukova, Elena, Zhdanova, Andrey, Babkin, Galina, Nechaeva, Olga, Barbarash, Elena, Rechkova, Roman, Libis, Elena, Kosmacheva, Tatyana, Rodionova, Irina, Ipatko, Alexander, Dreval, Nina, Petunina, Elena, Chernyavskaya, Alsu, Zalevskaya, Yuriy, Khalimov, Tatyana, Zykova, Anton, Edin, Ashot, Mkrtumyan, Shamil, Palyutin, Vyacheslav, Mareev, Leonid, Strongin, Olga, Ukhanova, Mikhail, Antsiferov, Davyd, Yakhontov, Leonid, Pimenov, Natalya, Koziolova, Konstantin, Nikolaev, Imad, Merai, Olga, Zanozina, Leyla, Gaysina, Mikhail, Arkhipov, Natalia, Malykh, Oksana, Rymar, Vladimir, Martynenko, Sofya, Malyutina, Polina, Ermakova, Marina, Kalashnikova, Bengt-Olov, Tengmark, Carl-Johan, Lindholm, Dan, Curiac, Ken, Eliasson, Erik, Rein-Hedin, Gregor, Guron, Inga, Soveri, Annette, Bruchfeld, Jonas, Spaak, Malin, Frank, Magnus, Löndahl, Hans, Larnefeldt, Margareta, Hellgren, Olof, Hellberg, Yong Mong Bee, Chee Fang Sum, Ru San Tan, Piyamitr, Sritara, Chaicharn, Deerochanawong, Chatlert, Pongchaiyakul, Natapong, Kosachunhanan, Bancha, Satirapoj, Ahmet, Temizhan, Ibrahim, Gul, Ramazan, Sari, Aytekin, Oguz, Mustafa, Tigen, Huseyin, Yilmaz, Ozer, Badak, Oner, Ozdogan, Talat, Tavli, Necmi, Eren, Murat, Cayli, Sedat, Ustundag, Yavuz, Yenicerioglu, Ismail, Kocyigit, Abdulbaki, Kumbasar, Idris, Sahin, Lee-Ming, Chuang, Ju-Ying, Jiang, Chien-Te, Lee, Der-Cherng, Tarng, Shih-Te, Tu, Mai-Szu, Wu, Ming-Ju, Wu, Chiz-Tzung, Chang, Cheng-Chieh, Hung, Liubov, Sokolova, Borys, Mankovsky, Dmytro, Kogut, Viktoriia, Chernikova, Kateryna, Malyar, Nonna, Kravchun, Volodymyr, Botsyurko, Vitaliy, Maslyanko, Liliya, Martynyuk, Oleksandr, Serhiyenko, Vasyl, Stryzhak, Halyna, Myshanych, Oleksandra, Donets, Iryna, Bondarets, Maryna, Vlasenko, Nataliia, Pertseva, Mariia, Grachova, Ivan, Smirnov, Larysa, Pererva, Ivan, Fushtey, Julia, Komisarenko, Anna, Isayeva, Carl, Meisner, Bobby, Khan, Louis, Maletz, Bradley, Dixon, Ahmed, Arif, Timothy, Jackson, Mirela, Ponduchi, Mahfouz El Shahawy, Salil, Nadkarni, Daniel, Urbach, Jorge, Paoli-Bruno, Henry, Lora, Umar, Farooq, Steven, Zeig, Lance, Rudolph, Nabil, Andrawis, William, Kaye, Jill, Meyer, Khalid, Bashir, Glenn, Heigerick, James, Smelser, Javier Ricardo Colomar, David, Scott, Brian, First, Stuart, Handelsman, Jose, Bautista, Rajesh, Patel, Stephen, Minton, Juan, Frias, Luis, Ramos-Gonez, John, Bertsch, Ali, Iranmanesh, Vivian, Fonseca, Michael, Yuryev, Larry, Popeil, Jose, Cardona, Sanjeev, Saxena, Santosh, Sharma, Edgar, Gonzalez, Richard, Solomon, Muhammad, Khan, Ahmed, Awad, David, Fitz-Patrick, Douglas, Linfert, David, Grant, Susan, Brian, Leon, Fogelfeld, Rafael, Canadas, Pablo, Pergola, Joseph, Soufer, Rakesh, Patel, Shujauddin, Valika, Jonathan, Winston, Allison, D, Maria, Caramori, Stanley, Koch, Anjay, Rastogi, Jonathan, Bornfreund, Michael, Rocco, Maxine, Hamilton, Luis, Garcia-Mayol, Peter, Weissman, Suzanne, Oparil, Gary, Ruoff, Kyaw, Soe, Gary, Korff, Robert, Busch, Alexander, Lurie, Israel, Hartman, Garfield, Samuels, Derek, Lejeune, Visal, Numrungroad, Stephen, Brietzke, Zeid, Kayali, Harold, Szerlip, Steven, Barag, Gilberto, Seco, Damaris, Vega, Osvaldo, Brusco, Camil, Kreit, Humberto, Cruz, Bharat, Mocherla, Sharma, Prabhakar, George, Fadda, Martin, Valdes, Eugene, Soroka, Ramin, Berenji, Sreedhara, Alla, Shweta, Bansal, Odugbesan, A, Karlton, Pettis, Masoud, Azizad, Idalia, Acosta, Atoya, Adams, William, Sanchez, Rosa, Suarez, Efrain, Reisin, Carlos, Herrera, Keung, Lee, Csaba, Kovesdy, Adam, Whaley-Connell, Aldo, Peixoto, Ronald, Mayfield, Mahendra, Jain, Earl, Martin, Paul, Norwood, Jonathan, Wise, Hugo, Romeu, Stephen, Halpern, Mustafa, Mandviwala, Thomas, Turk, Anna, Burgner, David, Bleich, Ankur, Doshi, Jose, Carpio, Jorge, Posada, Alexander, Magno, Samer, Nakhle, Gary, Goldstein, Caroline, Mbogua, Dierdre, Mcmullen, Dilawar, Ajani, Wayne, Kotzker, Nelson, Kopyt, Richard, Treger, Yusuf, Ruhullah, Sharon, Adler, Harjeet, Brar, Marc, Rendell, Dennis, Ross, Srinivasan, Beddhu, German, Hernandez, Sylvia, Rosas, M Sue Kirkman, Mohammed, El-Shahawy, Jeffrey, Rothman, Ahmad, Barakzoy, Aparna, Tamirisa, Sabrina, Benjamin, Michael, Bahrami, Prabir, Roy-Chaudhury, Ramprasad, Dandillaya, Gretel, Trullenque, Jose, Birriel, John, Flack, Karen, Johnson, Brenda, Lemus, Guillermo, Umpierrez, Geetha, Maddukuri, Kenneth, Jamerson, Christopher, Case, Patrick, Fluck, Saeed, Kronfli, Violet, Habwe, Bala, Subramanian, Tariq, Shafi, Rupesh, Raina, Roland, Fernando, Sourabh, Kharait, Carlos, Hernandez-Cassis, Raymond, Fink, Jamal, Hammoud, Amer, Al-Karadsheh, Manuel, Montero, Philip, Nicol, Jesus, Navarro, Michael, Shanik, Zia, Din, Francisco, Gonzalez-Abreu, Sam, Lerman, Claude, Galphin, John, Evans, Ashwini, Gore, Radica, Alicic, Mandeep, Sahani, Roberto, Pisoni, Tuan-Huy, Tran, Jeffrey, Ryu, Harvey, Serota, Nilda, Neyra, Richard, O Donovan, Sreedhar, Mandayam, Moustafa, Moustafa, Mark, Smith, Arvind, Krishna, Arjun, Sinha, Anuj, Bhargava, Kodangudi, Ramanathan, Soni, Dhanireddy, Stephen, Thomson, Romanita, Nica, Emaad, Abdel-Rahman, Mark, Barney, Mariana, Markell, Nauman, Shahid, David, Oliver, Tran, Khanh, Pham Nguyen Son, Lam VAN Hoang, Boi Ngoc Nguyen, Nguyen Minh Nui, Lan Phuong Tran, Fayzal, Ahmed, Dorothea, Urbach, Dirkie Jansen van Rensburg, Gracjan, Podgorski, Aslam, Amod, Sindeep, Bhana, Shaifali, Joshi, Essack, Mitha, Deepak, Lakha, Louis van Zyl, Trokis, J, Naresh, Ranjith, Mary, Seeber, Mohamed, Sarvan, Mohammed, Tayob, Brian, Rayner, Larry, Distiller, Heidi, Siebert, Mukesh, Joshi, Paul, Rheeder, Magdalena Madero Rovalo, Gustavo Solache Ortiz, Gustavo Méndez Machado, Rafael Valdez Ortiz, Juan Villagordoa Mesa, Saúl Irizar Santana, Sandro Avila Pardo, Jorge Escobedo de la Peña, Guillermo González Gálvez, Leobardo Sauque Reyna, Miriam Bastidas Adrian, Guillermo Fanghänel Salmón, Ramiro Gutiérrez Ochoa, Luis Nevarez Ruiz, Gabriel Ramos López, Alfredo Chew Wong, Arturo Saldaña Mendoza, Pedro García Hernández, José González González, Melchor Alpizar Salazar, José Lazcano Soto, Amaury, Roman-Miranda, Gregorio, Cortes-Maisonet, Liana, Turcu, Adriana, Dumitrescu, Gabriela, Radulian, Hortensia, Barbonta, Cristina, Mistodie, Georgeta, Vacaru, Alexandrina, Popescu, Adrian, Vlad, Silvia, Paveliu, Nicoleta, Mindrescu, Adrian, Albota, Ella, Pintilei, Lavinia, Pop, Gabriela, Negrisanu, Doina, Catrinoiu, Cornelia, Bala, Amorin, Popa, Iosif, Szilagyi, Ciprian, Constantin, Elena, Caceaune, Adriana, Onaca, Li Yuan Lee, Nor Azizah Aziz, Wan Mohd Izani Wan Mohamed, Wan Hasnul Halimi Bin Wan Hasan, Jeyakantha, Ratnasingam, Nik Nur Fatnoon Nik Ahmad, Rizmy Najme Khir, Norhaliza Mohd Ali, Masni, Mohamad, Chek Loong Loh, Joe, Eustace, John, Holian, Donal, Reddan, Yvonne, O Meara, Mensud, Hatunic, Zuzana, Ochodnicka, Dalibor, Sosovec, Andrej, Dzupina, Ingrid, Buganova, Jana, Babikova, Denisa, Spodniakova, Ruilope, L, Agarwal, R, Anker, S, Bakris, G, Filippatos, G, Nowack, C, Kolkhof, P, Joseph, A, Mentenich, N, Pitt, B, Trevisan, R, Pathology/molecular and cellular medicine, Diabetes Pathology & Therapy, and Diabetes Clinic

Subjects
Male, Endocrinology, Diabetes and Metabolism, Enfermedad cardiovascular, 030232 urology & nephrology, BAY 94-8862, Type 2 diabetes, 030204 cardiovascular system & hematology, Diabete, Kidney, Aparato circulatorio, Azúcar, chemistry.chemical_compound, Mineralocorticoid Receptor Antagonists/therapeutic use, 0302 clinical medicine, Medicine and Health Sciences, Diabetic Nephropathies, Myocardial infarction, Renal Insufficiency, Chronic, Aldosterone, Outcome, Mineralocorticoid Receptor Antagonists, RISK, COMPLICATIONS, Diabetes, Middle Aged, SPIRONOLACTONE, CHRONIC HEART-FAILURE, Treatment Outcome, Mineralocorticoid, Nephrology, Cardiovascular Diseases, Research Design, Disease Progression, Female, medicine.symptom, Cardiology and Cardiovascular Medicine, Type 2, Glomerular Filtration Rate, medicine.medical_specialty, Finerenone, Naphthyridines/therapeutic use, Renal function, Outcomes, 03 medical and health sciences, Clinical, Double-Blind Method, Diabetes mellitus, Internal medicine, medicine, Diabetes Mellitus, Humans, Naphthyridines, Renal Insufficiency, Chronic, ANTAGONIST, Sistema cardiovascular, Aged, Patient-Oriented, Translational Research: Research Article, Diabetic Nephropathies/complications, Renal Insufficiency, Chronic/drug therapy, RECEPTOR, Aldosterone, Clinical, Diabetes, Kidney, Mineralocorticoid, Outcomes, business.industry, Cardiovascular Diseases/epidemiology, Diabetes Mellitus, Type 2/complications, MILD, WORSENING RENAL-FUNCTION, EFFICACY, medicine.disease, chemistry, Diabetes Mellitus, Type 2, Spironolactone, Albuminuria, business, Kidney disease, Follow-Up Studies
Abstract

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m2 and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.

Published
2019

4. Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE)

Author

Jose Antônio Marin-Neto, Jeanne Clark, Alfredo Ramirez, Philip Böhme, Victor Gurevich, Miguel Urina, Valdis Pirags, Heather Lochnan, Jan Cornel, Bu Yeap, Ricardo Bohorquez, Marina F Kalashnikova, Aldo Pietro Maggioni, ALVARO AVEZUM, Igor Bondarenko, Monica Acevedo, Francesco Cacciatore, Weiping Jia, B. L. Gregoire Nyomba, Neslihan Bascil Tutuncu, Anastasia F Hutchinson, Sudeep K, Moti Kashyap, Adrian Vlad, Aivars Lejnieks, Jeong-Taek Woo, Shirley Jansen, Cristina Facanha, Laura Bryan, Louise Bordeleau, Patricio Lopez-Jaramillo, Adriana Forti, Flavia Lucia Lombardo, Malgorzata Sikora-Frac, Peter Colman, Olga Bulkina, ERNESTO GERMAN CARDONA MUÑOZ, Melanie Davies, JAIME CARMONA-HUERTA, Hertzel Gerstein, Jackie Bosch, Alina Babenko, Philip Aylward, Qifu Li, Yury Vasyuk, Asem Ali, Anna Novials, Andrzej Budaj, and Anne Taylor

Subjects
Male, medicine.medical_specialty, Randomization, Endocrinology, Diabetes and Metabolism, Insulin Glargine, 030204 cardiovascular system & hematology, Placebo, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Risk Factors, law, Internal medicine, Diabetes mellitus, Fatty Acids, Omega-3, Internal Medicine, medicine, Humans, Hypoglycemic Agents, 030212 general & internal medicine, Myocardial infarction, Stroke, Aged, Proportional Hazards Models, Glycated Hemoglobin, Advanced and Specialized Nursing, Insulin glargine, business.industry, Hazard ratio, Middle Aged, medicine.disease, Metformin, Sulfonylurea Compounds, Treatment Outcome, Endocrinology, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Dietary Supplements, Female, business, Follow-Up Studies, medicine.drug
Abstract

OBJECTIVE The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutral effects of insulin glargine on cardiovascular outcomes and cancers and reduced incident diabetes in high–cardiovascular risk adults with dysglycemia after 6.2 years of active treatment. Omega-3 fatty acids had neutral effects on cardiovascular outcomes. The ORIGIN and Legacy Effects (ORIGINALE) study measured posttrial effects of these interventions during an additional 2.7 years. RESEARCH DESIGN AND METHODS Surviving ORIGIN participants attended up to two additional visits. The hazard of clinical outcomes during the entire follow-up period from randomization was calculated. RESULTS Of 12,537 participants randomized, posttrial data were analyzed for 4,718 originally allocated to insulin glargine (2,351) versus standard care (2,367), and 4,771 originally allocated to omega-3 fatty acid supplements (2,368) versus placebo (2,403). Posttrial, small differences in median HbA1c persisted (glargine 6.6% [49 mmol/mol], standard care 6.7% [50 mmol/mol], P = 0.025). From randomization to the end of posttrial follow-up, no differences were found between the glargine and standard care groups in myocardial infarction, stroke, or cardiovascular death (1,185 vs. 1,165 events; hazard ratio 1.01 [95% CI 0.94–1.10]; P = 0.72); myocardial infarction, stroke, cardiovascular death, revascularization, or hospitalization for heart failure (1,958 vs. 1,910 events; 1.03 [0.97–1.10]; P = 0.38); or any cancer (524 vs. 529 events; 0.99 [0.88–1.12]; P = 0.91) or between omega-3 and placebo groups in cardiovascular death (688 vs. 700; 0.98 [0.88–1.09]; P = 0.68) or other outcomes. CONCLUSIONS During >6 years of treatment followed by >2.5 years of observation, insulin glargine had neutral effects on health outcomes and salutary effects on metabolic control, whereas omega-3 fatty acid supplementation had no effect.

Published
2015

5. Early age at menarche: a risk factor for overweight or obesity in patients with type 1 diabetes living in urban areas?

Author

Maria Cristina Foss-Freitas, Luis Eduardo P. Calliari, Sergio Atala Dib, Carlos Antonio Negrato, Cristina Facanha, Adriana Forti, Renan Montenegro Junior, Roberta Cobas, and MARILIA GOMES

Subjects
Adult, medicine.medical_specialty, Urban Population, Endocrinology, Diabetes and Metabolism, Overweight, Lower risk, Endocrinology, Risk Factors, Internal medicine, Internal Medicine, medicine, Humans, Obesity, Risk factor, Menarche, Type 1 diabetes, business.industry, Age Factors, General Medicine, Odds ratio, medicine.disease, Cross-Sectional Studies, Diabetes Mellitus, Type 1, Cardiovascular Diseases, Glycemic Index, Female, medicine.symptom, business, Body mass index, Brazil, Demography
Abstract

a b s t r a c t Aims: Determine the relationship between age at menarche, glycemic control and cardiovascular risk factors in patients with type 1 diabetes living in urban areas. Methods: This was a multicenter cross-sectional study conducted in 20 cities in four Brazilian geographic regions. Data were obtained from 1527 female patients, 59.3% Caucasians, aged 25.1 10.6 years. Diabetes duration was 11.4 8.1 years. Age at menarche was stratified in four groups: 8‐11 (group 1, early menarche), 12 (group 2), 13 (group 3) and 14‐18 years (group 4, late menarche). Results: The mean age at menarche was 12.7 1.7 years without difference among geographical regions, economic status, level of care and ethnicity. BMI had an inverse correlation with age at menarche (r = 0.14, p < 0.001). No significant difference was observed among the four groups for blood pressure, lipid profile and diabetes-related chronic complications. Logistic regression analysis showed that early age at menarche, 8‐11 years (odds ratio (ORs) 1.77 [1.30‐2.41], p < 0.001) and duration of diabetes [ORs 1.01 (1.00‐1.03), p = 0.02], were related to greater risk of patients’ overweight or obesity; adherence to diet [ORs 0.78 (0.60‐0.93), p = 0.01], physical activity [ORs 0.75 (0.94‐0.94), p = 0.01], and lower insulin dose (U/kg) [ORs 0.54 (0.59‐0.90), p = 0.001] were related to lower risk for overweight or obesity. Conclusions: Early menarche occurred in 23.4% of women with type 1 diabetes living in Brazilian urban areas and was strongly associated with overweight/obesity in pubertal/adult life. Further studies are warranted to establish the relationship between early menarche, glycemic control and cardiovascular risk factors. # 2014 Published by Elsevier Ireland Ltd.

Published
2014

6. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia

Author

David Clayton, Robert Cuddihy, Jose Antônio Marin-Neto, Jeanne Clark, Esra Hatipoglu, Mohd Shazli Draman, Alfredo Ramirez, Philip Böhme, Victor Gurevich, Miguel Urina, Angel L. Fernández, Maja Cigrovski Berkovic, Valdis Pirags, Evgeny Shkolnik, Alexander Vonbank, Salim Yusuf, Heather Lochnan, Jan Cornel, Bu Yeap, Tatiana Adasheva, Giuseppe Derosa, Aldo Pietro Maggioni, ALVARO AVEZUM, Igor Bondarenko, Monica Acevedo, Francesco Cacciatore, A.S. Ametov, Weiping Jia, Iana Orlova, Anders Waldenström, B. L. Gregoire Nyomba, Neslihan Bascil Tutuncu, Tristan Richardson, Anastasia F Hutchinson, Vladimir Zadionchenko, Sudeep K, Moti Kashyap, Adrian Vlad, Aivars Lejnieks, Jeong-Taek Woo, Fernando Lanas, Nicolae Hancu, Kurt Boman, Cristina Facanha, Laura Bryan, Louise Bordeleau, Patricio Lopez-Jaramillo, Adriana Forti, Flavia Lucia Lombardo, Gunnar Gislason, Malgorzata Sikora-Frac, Peter Colman, Veronique Kerlan, Olga Bulkina, Melanie Davies, Maira Marino, JAIME CARMONA-HUERTA, Hertzel Gerstein, Jackie Bosch, Carlos Morillo, Alina Babenko, Philip Aylward, SONIA GAZTAMBIDE, Yury Vasyuk, Asem Ali, Ragnar Martin Joakimsen, Anna Novials, Andrzej Budaj, Anne Taylor, Department of General Surgery. Surgical Oncology Unit, Reina Sofía University Hospital, Population Health Research Institute, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Service d'Endocrinologie (CHRU - Endocrino), and Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)

Subjects
Male, MESH: Treatment Failure, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Insulin Glargine, 030204 cardiovascular system & hematology, MESH: Intention to Treat Analysis, MESH: Proportional Hazards Models, chemistry.chemical_compound, 0302 clinical medicine, MESH: Cholesterol, dysglycemia, MESH: Fatty Acids, Omega-3, MESH: Double-Blind Method, Treatment Failure, 030212 general & internal medicine, MESH: Incidence, MESH: Aged, MESH: Middle Aged, Dysglycemia, cardiovascular events, Incidence, General Medicine, MESH: Follow-Up Studies, Middle Aged, INFARTO DO MIOCÁRDIO, Intention to Treat Analysis, 3. Good health, Insulin, Long-Acting, Cholesterol, Cardiovascular Diseases, n-3 fatty acid, Cardiology, Drug Therapy, Combination, Female, medicine.drug, MESH: Diabetes Mellitus, Type 2, MESH: Triglycerides, medicine.medical_specialty, MACE diabetes glargin, 03 medical and health sciences, Pharmacotherapy, Double-Blind Method, Internal medicine, Diabetes mellitus, MESH: Hypoglycemic Agents, Fatty Acids, Omega-3, Glucose Intolerance, medicine, Humans, Hypoglycemic Agents, Triglycerides, MESH: Glucose Intolerance, Aged, Proportional Hazards Models, Intention-to-treat analysis, MESH: Humans, business.industry, Insulin glargine, Proportional hazards model, Insulin, MESH: Cardiovascular Diseases, medicine.disease, MESH: Male, MESH: Drug Therapy, Combination, Endocrinology, Diabetes Mellitus, Type 2, chemistry, Heart failure, MESH: Insulin, Long-Acting, business, MESH: Female, Follow-Up Studies
Abstract

International audience; BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P

Published
2012

7. Basal insulin and cardiovascular and other outcomes in dysglycemia

Author

David Clayton, Robert Cuddihy, Jose Antônio Marin-Neto, Esra Hatipoglu, Mohd Shazli Draman, Alfredo Ramirez, Philip Böhme, Victor Gurevich, Miguel Urina, Angel L. Fernández, Maja Cigrovski Berkovic, Valdis Pirags, Evgeny Shkolnik, Alexander Vonbank, Salim Yusuf, Heather Lochnan, Jan Cornel, Bu Yeap, Tatiana Adasheva, Giuseppe Derosa, Aldo Pietro Maggioni, ALVARO AVEZUM, Igor Bondarenko, Monica Acevedo, Francesco Cacciatore, A.S. Ametov, Weiping Jia, Anders Waldenström, B. L. Gregoire Nyomba, Neslihan Bascil Tutuncu, Tristan Richardson, Anastasia F Hutchinson, Vladimir Zadionchenko, Sudeep K, Moti Kashyap, Adrian Vlad, Aivars Lejnieks, Jeong-Taek Woo, Fernando Lanas, Nicolae Hancu, Kurt Boman, Cristina Facanha, Laura Bryan, Louise Bordeleau, Patricio Lopez-Jaramillo, Adriana Forti, Flavia Lucia Lombardo, Gunnar Gislason, Malgorzata Sikora-Frac, Peter Colman, Veronique Kerlan, Olga Bulkina, Melanie Davies, JAIME CARMONA-HUERTA, Hertzel Gerstein, Jackie Bosch, Carlos Morillo, Alina Babenko, Philip Aylward, SONIA GAZTAMBIDE, Yury Vasyuk, Asem Ali, Ragnar Martin Joakimsen, Anna Novials, Andrzej Budaj, Anne Taylor, Department of Medicine (DM - McMaster), McMaster University [Hamilton, Ontario], Population Health Research Institute, Institut Universitaire de Cardiologie (QUEBEC - IUCP), Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Université Laval [Québec] (ULaval)-Université Laval [Québec] (ULaval), Department of General Surgery. Surgical Oncology Unit, Reina Sofía University Hospital, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Service d'Endocrinologie (CHRU - Endocrino), and Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)

Subjects
Blood Glucose, Male, MESH: Hypoglycemia, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Insulin Glargine, Type 2 diabetes, MESH: Hospitalization, 030204 cardiovascular system & hematology, MESH: Intention to Treat Analysis, Impaired glucose tolerance, MESH: Proportional Hazards Models, 0302 clinical medicine, MESH: Cholesterol, MESH: Fatty Acids, Omega-3, dysglycemia, MESH: Double-Blind Method, Basal insulin, MESH: Incidence, MESH: Aged, MESH: Middle Aged, Incidence, Hazard ratio, Fasting, General Medicine, MESH: Follow-Up Studies, Middle Aged, Intention to Treat Analysis, 3. Good health, Hospitalization, Insulin, Long-Acting, Cholesterol, Cardiovascular Diseases, Drug Therapy, Combination, Female, medicine.drug, MESH: Diabetes Mellitus, Type 2, MESH: Triglycerides, medicine.medical_specialty, MACE diabetes glargin, MESH: Fasting, HIPOGLICEMIA, 030209 endocrinology & metabolism, Hypoglycemia, 03 medical and health sciences, Double-Blind Method, Diabetes mellitus, Internal medicine, MESH: Hypoglycemic Agents, Fatty Acids, Omega-3, Glucose Intolerance, medicine, Humans, Hypoglycemic Agents, Triglycerides, MESH: Glucose Intolerance, Aged, Proportional Hazards Models, MESH: Humans, business.industry, Insulin glargine, Insulin, MESH: Cardiovascular Diseases, medicine.disease, Impaired fasting glucose, MESH: Male, basal insulin, MESH: Drug Therapy, Combination, Endocrinology, Diabetes Mellitus, Type 2, MESH: Blood Glucose, MESH: Insulin, Long-Acting, business, MESH: Female, Follow-Up Studies
Abstract

International audience; BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).

Published
2012

8. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Author

Maryna Vlasenko, Yury Shvarts, Renzo Cordera, Zhanna D. Kobalava, Lyudmila Suplotova, Gregory Arutyunov, Irina Gurieva, Sergey Nedogoda, Adriana Forti, Olga Reshetko, Jose Sgarbi, Andriy Bazylevych, Cecilia Jimeno, Carlos Jerjes - Sanchez, and Iurii Rudyk

Subjects
Adult, Blood Glucose, Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Urology, Adamantane, Type 2 diabetes, Saxagliptin, Placebo, chemistry.chemical_compound, Endocrinology, Double-Blind Method, Diabetes mellitus, Internal Medicine, Medicine, Humans, Hypoglycemic Agents, Glycated Hemoglobin, Dipeptidyl-Peptidase IV Inhibitors, business.industry, Area under the curve, Dipeptides, Fasting, Middle Aged, medicine.disease, Postprandial Period, Metformin, Postprandial, Treatment Outcome, Tolerability, chemistry, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, business, medicine.drug
Abstract

Aim: The study aim was to evaluate the efficacy and safety of initial combination therapy with saxagliptin þ metformin vs. saxagliptin or metformin monotherapy in treatment-naive patients with type 2 diabetes (T2D) and inadequate glycaemic control. Methods: In this multicentre, randomized, double-blind, active-controlled phase 3 trial, 1306 treatment-naive patients with T2D � 18 to � 77 years, glycosylated haemoglobin (HbA1c) � 8t o� 12%, fasting C-peptide concentration � 1.0 ng/ml, body mass index � 40 kg/m 2 were randomized to receive saxagliptin 5 mg þ metformin 500 mg, saxagliptin 10 mg þ metformin 500 mg, saxagliptin 10 mg þ placebo or metformin 500 mg þ placebo for 24 weeks. From weeks 1-5, metformin was uptitrated in 500-mg/day increments to 2000 mg/day maximum in the saxagliptin 5 mg þ metformin, saxagliptin 10 mg þ metformin and metformin þ placebo treatment groups. The main outcome measure was HbA1c change from baseline to week 24. Selected secondary outcomes included change from baseline to week 24 in fasting plasma glucose (FPG), pro- portion of patients achieving HbA1c

Published
2009

9. Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes: the genetics, outcomes, and lipids in type 2 diabetes (GOLD) study

Author

Maria C, Izar, Tatiana, Helfenstein, Silvia S, Ihara, Waldir G, Relvas, Andreza O, Santos, Simone C, Fischer, Leonor E, Pinto, Ieda E, Lopes, Daniel R, Pomaro, Marilia I, Fonseca, Luis C, Bodanese, Emilio H, Moriguchi, Jose F, Saraiva, Luiz, Introcaso, Agnaldo D, Souza, Marileia, Scartezini, Kerginaldo P, Torres, Leao, Zagury, Paulo C, Jardim, Eduardo A, Costa, Lucia H, Tacito, Adriana, Forti, Maria E, Magalhaes, Antonio R, Chacra, Marcelo C, Bertolami, Andreia A, Loures-Vale, Marco A, Barros, Hermes T, Xavier, Ruy, Lyra, Dikran, Argamanijan, Armenio, Guimaraes, Jose P, Novazzi, Nelson, Kasinski, Abrahao, Afiune, Tania L, Martinez, Raul D, Santos, Jose C, Nicolau, Luiz A, Cesar, Rui M, Povoa, Antonio C, Carvalho, Sang W, Han, and Francisco A, Fonseca

Subjects
Adult, Aged, 80 and over, Male, Polymorphism, Genetic, Myocardial Infarction, Middle Aged, Lipids, Risk Assessment, Lipoprotein Lipase, Logistic Models, Phenotype, Diabetes Mellitus, Type 2, Gene Frequency, Risk Factors, Case-Control Studies, Odds Ratio, Humans, Female, Genetic Predisposition to Disease, Prospective Studies, Brazil, Aged
Abstract

The association of polymorphisms affecting lipid metabolism with the risk of myocardial infarction (MI) in type 2 diabetes mellitus was investigated. The Genetics, Outcomes and Lipids in type 2 Diabetes (GOLD) Study is a prospective, multicenter study, conducted on 990 patients presenting diabetes and MI (n=386), or diabetes without previous manifestation of stroke, peripheral or coronary arterial disease (n=604), recruited from 27 institutions in Brazil. APO A1 (A/G -75 and C/T +83) and APO C3 (C/G 3'UTR) non-coding sequences, CETP (Taq 1B), LPL (D9N), APO E (epsilon2, epsilon3, epsilon4,), PON-1 (Q192R), and two LCAT variants Arg(147)--Trp and Tyr(171)--Stop were tested by PCR-RFLP. There was a higher prevalence of LPL DN genotype (19% vs.12%, p=0.03) and a higher frequency of the N allele (11% vs. 7%) among subjects with MI when compared to controls, with an odds ratio of MI for carriers of 9N allele of 2.46 (95% CI=1.79-3.39, p0.0001). This association was present in men and women, in non-smokers and in hypertensive patients. A logistic regression model including gender, duration of diabetes, systolic blood pressure, HDL-C, left ventricle hypertrophy and D9N polymorphism showed that the latter still remained significantly associated with MI (OR=1.50, 95% CI=1.02-2.25, p=0.049). These findings suggest that D9N polymorphism can be a useful risk marker for myocardial infarction and that further potential candidate genes should be screened for exploratory analysis and for future therapeutic intervention in diabetes.

Published
2008

10. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)

Author

Filip K Knop, Anthony Kam, Jose Antônio Marin-Neto, Alfredo Ramirez, Philip Böhme, Miguel Urina, Angel L. Fernández, Bjarne Nørgaard, Valdis Pirags, Margret Leosdottir, Salim Yusuf, Heather Lochnan, Kina Höglund, Bu Yeap, Ricardo Bohorquez, Marina F Kalashnikova, Fredrik Folke, ALVARO AVEZUM, Igor Bondarenko, Monica Acevedo, Francesco Cacciatore, Weiping Jia, Sergio Grunbaum, Filipa Costa, Neslihan Bascil Tutuncu, Hermione Price, Sudeep K, Aivars Lejnieks, Jeong-Taek Woo, Martin Magnusson, Assoc. Prof. Darko Katalinic, M.D., Ph.D., Aylin YILDIRIR, Laura Bryan, Patricio Lopez-Jaramillo, Adriana Forti, Flavia Lucia Lombardo, Malgorzata Sikora-Frac, José Ramón González Juanatey, Peter Colman, Olga Bulkina, Melanie Davies, Hertzel Gerstein, Jackie Bosch, Alina Babenko, Qifu Li, Alvaro Reyes, Cecilia Jimeno, Yury Vasyuk, Rodrigo Bagur, Sanja Barsic Ostojic, Anna Novials, Andrzej Budaj, and Anne Taylor

Subjects
Blood Glucose, Male, medicine.medical_specialty, International Cooperation, medicine.medical_treatment, MACE diabetes glargin, Insulin Glargine, Severity of Illness Index, Drug Administration Schedule, Impaired glucose tolerance, chemistry.chemical_compound, Reference Values, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Insulin, Aged, Probability, Proportional Hazards Models, Glycemic, Glycated Hemoglobin, Glucose tolerance test, Dose-Response Relationship, Drug, medicine.diagnostic_test, Insulin glargine, business.industry, Patient Selection, Glucose Tolerance Test, Middle Aged, Impaired fasting glucose, medicine.disease, Survival Analysis, origin, glargine, Insulin, Long-Acting, Treatment Outcome, Endocrinology, Diabetes Mellitus, Type 2, chemistry, Cardiovascular Diseases, Research Design, Female, Glycated hemoglobin, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies, medicine.drug
Abstract

ims: Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes arise due to insufficient insulin secretion and are risk factors for cardiovascular (CV) events. Thus, targeting normal fasting glucose levels with insulin may reduce CV events. Previous studies suggest that omega-3 fatty acid supplements may reduce CV death ; however, their effect in high- risk dysglycemic individuals is not known. Methods: People aged > or = 50 years with evidence of CV disease and with IFG, IGT, newly detected or established diabetes (on 0 or 1 oral agent), and a local glycated hemoglobin < 150% of the upper limit of normal for that assay were recruited and allocated to (a) either 1 daily injection of insulin glargine with the dose titrated to achieve a fasting plasma glucose < or = 5.3 mmol/L (95 mg/dL), or standard glycemic care ; and (b) either omega-3-acid ethyl esters 90 (1 g consisting of EPA 465 mg and DHA 375 mg) or identical placebo, according to a 2 x 2 factorial design. The 2 different primary outcomes for the insulin and omega-3 fatty acid arms are CV events and CV death, respectively. Results: A total of 12, 612 (mean age 64, 35% women) people in 40 countries were randomized during a 2-year period ending December 2005. Eighty-two percent had established diabetes, 6% had new diabetes, and 12% had IGT or IFG ; the mean fasting plasma glucose was 7.3 mmol/L (131 mg/dL). Conclusions: The ORIGIN trial will determine whether or not either or both of these interventions can reduce CV events.

Published
2008

11. Lab methods, progression & risk factors for CKD - 1

Author

Ligia Regina Franco Sansigolo Kerr, Bjørn Egil Vikse, Paulo Mota, Michel Daudon, Sue Carr, Claudia Modesto Velludo, M. Turan Gumus, Djordje Miljković, Nam Ju Heo, Noriaki Iino, Jae-Yoon Park, Giuseppe Garigali, Janusz Solski, Masashi Suzuki, Krzysztof Janicki, Fabiana M. R. Sanches, Luciana Almeida, Viviane O. Leal, Plamen H. Yovchevski, Reem Al-Jayyousi, Katia Toffolo, Nauman Tarif, Agnieszka Grzebalska, Panayotis Foundas, Sotirios Mikros, Natalia Polanco, Andrzej Ksiazek, Takashi Takei, Ciriaco Carru, José M. López-Novoa, Ashraf El-Saeed, Thomas Elung-Jensen, Hayne Cho Park, Tayfun Eyileten, Hasan Kayabasi, Etienne Cavalier, Victor Gutierrez-Millet, Marcelo M. Lemos, Yoshiki Nishizawa, M. Emin Yilmaz, Alice C. Smith, Abdel-Bassit El-Shaarawy, Svend Strandgaard, Ana Huerta, Catherine Bessin, Yosuke Nakayama, Laura Sola, Eirini Karvela, Zulfikar Yilmaz, Aikaterini Tselenti, Maria P. Hernandez-Fuentes, Francisco J. López-Hernández, Santosh Kumar Singh, Caroline Freguin, Manuel Praga, Jean-Marie Krzesinski, Deepak Jain, Christine Cleaud, Morad Amar, Dusan Bastac, Tiziana Cena, Abdulkareem Al Suwaida, Alexandre Braga Libório, Kayser Caglar, Sergio Antonio Draibe, Michel Godin, Nikolaos Tentolouris, Régis Radermecker, Tetsuro Takeda, Bruno Legallicier, Lucia Andrade, Inkara Mansurova, Pinar Sezgin Karatas, Ken Tsuchiya, Fabrice Bauer, Simona Verdesca, Denis Fouque, Maria Eugênia Fernandes Canziani, Bjarne M. Iversen, Ayuko Fujiu, Maria Heloisa M. Shimizu, Giacomina Loriga, Hajeong Lee, Durdana Hammad, Lorentz Irgens, Dominique Guerrot, Marcelle Rorive, Dmitry Putintsev, Masafumi Kurajoh, Pierre Delanaye, Hari Krishan Aggarwal, João L. Viana, Tetsuo Shoji, Han Kyu Lee, Danica Bukvic, Jocelyne Drai, Ryotaro Ando, Evgeniy Goshev, Shoko Tsuchikura, Adriano Luiz Ammirati, Nikolaos Katsilambros, Virginia Lee, Alper Sonmez, Maria Aparecida Dalboni, Suhnggwon Kim, Maurilo Leite, Christina L. Olsson, Keiko Yamamoto, Nicolette C. Bishop, Hak Jong Lee, Dong-Wan Chae, Fitsum Guebre-Egziabher, R. Swaminathan, Yusuf Oguz, Eun Jin Cho, Alicia Sans, Ivko Maric, Andrzej Drop, Seiji Ueda, Alan Bevington, W. Arkouche, Yaremi Quiros, Biserka Tirmenstajn Jankovic, Julie Lin, Imtiaz Shah, Dede Sit, Nigel J. Brunskill, Milton Urrutia, Sho-ichi Yamagishi, Masaaki Inaba, Carlos Martinez-Salgado, Ana M. Blazquez-Medela, Elisa Lazzarich, Ki Young Na, Zhannat Kuanshalieva, Elena Gutierrez-Solis, Eduardo Gutiérrez, Felipe Rizzetto, Torbjørn Leivestad, Mahir Gulec, Jamal Al Wakeel, Selim Kilic, Jorge González, Ali Kemal Kadiroglu, Adriana Forti, Lucyna Janicka, Tetsuya Ogawa, Maria Mylonopoulou, Jeong Myung Ahn, Carla Cavalheiro da Silva Lemos, Keiko Uchida, Carmine Zoccali, Geraldo Bezerra da Silva Junior, Joel Claudio Heimann, Renato Watanabe, Antonio Carlos Seguro, Shinsuke Yamada, Roberta Fenoglio, Isabel Fuentes-Calvo, Deise de Boni Monteiro de Carvalho, Eduardo Hernández, Ljubica Djukanovic, Rolv Skjærven, Masami Bessho, Bruno Cauliez, Seiya Okuda, Hans Bendz, Matthew Hall, Nelson Mazzuchi, Mahmut Ilker Yilmaz, Ho Jun Chin, Ana Hernández, JoséWellington Lima, Emma Schwedt, Emma L. Clapp, Natalia Shcherban, Kosta Kostov, Yasuo Imanishi, John Feehally, Fogazzi Giovanni Battista, Eiji Ishimura, Nada Dimkovic, Maki Toyonaga, Paulo Roberto Santos, Anne-Lise Kamper, Elizabeth De Francesco Daher, Kei Fukami, Ayako Fujimi-Hayashida, Lene Boesby, Anne-Marie L. Seymour, George Kosmadakis, Rachel Bregman, Abdülgaffar Vural, Abdulrauf Chaudhary, Mujdat Yenicesu, Luciana Nicolau, Patrizia Pergolini, Gary Curhan, Andrea Airoldi, Grzegorz Staskiewicz, André Scheen, Yury Landyshev, Piero Stratta, Visnja Lezaic, David Goldsmith, Tae Woo Lee, Marco Aurélio de Biato, Esther González, Ann Chalmers, Sergey Tseluyko, Daniele Venturoli, Cristina Scheeffer, Frances Valéria Costa e Silva, Ivana Novakovic, Casimiro Valle Domínguez, Konstantinos Katsaros, Bengt Rippe, Sung-Il Hwang, Giorgio Bellomo, Pablo Ríos, Ikue Kobayashi, Elzbieta Czekajska, Yusuke Kaida, Lilian Cuppari, Nancy De Souza, Denise Mafra, Mutlu Saglam, William Smith, Daniele N. Ferreira, Yukako Sawara, Angelo Zinellu, Croci Daniela, Fumitake Gejyo, Yoshiharu Tsubakihara, Maria Inês Barreto Silva, Marija Mostarica-Stojkovic, Adilson C. Rodrigues, Andrea Satta, Izabella Z.A. Pawluczyk, Maria Ayako Kamimura, Enrique Morales, Dariusz Duma, Akihiko Saito, Zorica Krcunovic, Nami Matsuda, Hidenori Koyama, Hiromichi Suzuki, Stavros Antonopoulos, Masanori Emoto, Michael Bubenheim, Odile Rivault, and Kosaku Nitta

Subjects
03 medical and health sciences, Transplantation, medicine.medical_specialty, 0302 clinical medicine, Nephrology, business.industry, 030232 urology & nephrology, Medicine, business, Intensive care medicine
Published
2009

12. Pericarditis tuberculosa complicada con taponamiento cardíaco

Author

Mario Lora Andosilla, Adriana Fortich Salvador, Liney Mendoza Suárez, Karina Ruiz Caez, Ariel Bello Espinosa, Fernando De la Vega del Risco, Sandra Herrera Lomonaco, and Carolina Sánchez Romero

Subjects
Pericarditis tuberculosa, Derrame pericárdico, Taponamiento cardíaco., Medicine (General), R5-920
Abstract

Introducción: la pericarditis tuberculosa (PT) es una complicación potencialmente letal de la infección por el Mycobaterium tuberculosis. Ocasionalmente puede llegar a estadios avanzados y generar taponamiento cardíaco. Caso Clínico: se presenta el caso clínico de paciente de 39 años de edad, fármacodependiente y portador de VIH, con tratamiento irregular. Atendido en el Hospital Universitario del Caribe en Cartagena, Colombia. El paciente ingresó por sintomatología respiratoria y cardiovascular, por lo cual fue considerada inicialmente la presencia de falla cardíaca y neumonía. Posteriormente se instalaron manifestaciones clínicas sugestivas de taponamiento cardíaco, confirmadas por radiografía de tórax y ecocardiograma. El taponamiento fue manejado con punción y ventana pericárdica. El diagnóstico de PT fue confirmado por biopsia del pericardio y manejado con medicamentos antituberculosos, con adecuada mejoría. Conclusiones: la PT es un cuadro crónico que puede llevar a una fase aguda, de elevada mortalidad, como es el taponamiento cardíaco. La elevada sospecha clínica, la imagenología, el laboratorio y la histopatología, permiten confirmarlos y la intervención oportuna reducir la morbilidad y mortalidad. Rev.cienc.biomed. 2014;5(2):329-335.

Published
2020
Full Text
View/download PDF

13. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.

Author

Adriana Forti, Eduardo Garcia Garcia, Maria B. Yu, Maria C. Jimenez, Robert G. Brodows, and Juliana H. Oliveira

Subjects
*DRUG efficacy, *LATIN Americans, *PEOPLE with diabetes, *METFORMIN, *SULFONYLUREAS, *BREAKFASTS, *DISEASES
Abstract

Objective: To evaluate whether exenatide administered before breakfast and dinner (BD) or before lunch and dinner (LD) provided similar glycemic control in Latin American patients with type 2 diabetes mellitus (T2DM) who consume a small breakfast.Methods: In this open-label, 2-arm study, patients taking metformin, sulfonylureas, and/or thiazolidinediones were randomized to exenatide before BD or before LD (5-μg exenatide for 4 weeks, then 10-μg exenatide for 8 weeks). Treatment assignment was determined by a computer-generated random sequence using an interactive response system. Patients were eligible for study inclusion if they consumed <15% of their total caloric intake at breakfast. The primary endpoint was HbA1c change from baseline to endpoint. Secondary endpoints included fasting serum glucose (FSG) level, 7-point SMBG profile, and safety. Clinicaltrials.gov Identifier: NCT00359879.Results: 377 participants (55% female, age 54 ± 10 years, weight 82 ± 15 kg, BMI 31 ± 4 kg/m2, HbA1c 8.4 ± 0.9%; mean ± SD) from Brazil and Mexico were randomized to study treatment. HbA1c reduction with exenatide administration before BD was non-inferior to administration before LD (mean difference between (LD–BD) treatments: 0.14%; 95% CI −0.04 to 0.32%, p=0.120). Both treatments resulted in statistically significant HbA1c reductions at endpoint (BD −1.2% and LD −1.1%, respectively, p<0.001). In Brazil, the non-inferiority criteria were met for HbA1c reduction between treatment arms (−0.12%; CI −0.37 to 0.13%, p=0.344), whereas in Mexico, there was a difference favoring exenatide administration before BD (0.41%; CI 0.16 to 0.66%, p=0.002). At endpoint, there were no statistical significant differences between the BD and LD arms in mean change in FSG (0.50 mmol/L; CI −0.02 to 1.02 mmol/L, p=0.058) and daily mean change in SMBG (0.19 mmol/L; CI −0.17 to 0.54 mmol/L, p=0.295). The rates of symptomatic hypoglycemia (5.2 events/patient-year vs. 6.1 events/patient-year) and nausea (23% vs. 25%), were similar between the BD and LD arms, respectively. A limitation of the study design was that caloric intake of patients and meal times were not monitored.Conclusions: In T2DM patients who consume a small breakfast, exenatide administration before breakfast or lunch resulted in significant improvement in glycemic control. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

14. Causa infrecuente de encefalitis por Staphylococcus aureus, reporte de un caso

Author

Luis M. Polo, Martín Torres, Luis Taboada, Randy Guerra, Adriana Fortich S, Luis A. Díaz, José M. Cañas, Laura Álvarez, José Dussán, and Andrés de León

Subjects
Encefalitis por Staphylococcus aureus meticilino sensible (DECS), Neurology. Diseases of the nervous system, RC346-429
Abstract

Se presenta un caso de encefalitis por Staphylococcus aureus meticilino sensible. Se trata de una paciente de sexo femenino, de 20 años de edad, quien fue atendida en la Fundación Centro Colombiano de Epilepsia y Enfermedades Neurológicas, de Cartagena, por presentar cefalea, progresivo deterioro del estado cognitivo y focalidad neurológica súbita con limitación a la emisión del lenguaje. Hallazgos en cultivo de LCR revelan crecimiento de Staphylococcus aureus meticilino sensible. La evolución de esta paciente fue satisfactoria. Se hace una revisión del caso, se realiza análisis de infrecuencia de encefalitis por Staphylococcusa ureus meticilino sensible sin foco de infección primario establecido.

Published
2015
Full Text
View/download PDF

15. Evaluation of a 1-h 75-g oral glucose tolerance test in the diagnosis of gestational diabetes

Author

Campos, M. A. A., Reichelt, A. A. J., Façanha, C., adriana forti, and Schmidt, M. I.

Subjects
lcsh:R5-920, Sensitivity, endocrine system diseases, lcsh:Biology (General), Diagnosis, 1-h OGTT, Specificity, Macrosomia, lcsh:Medicine (General), lcsh:QH301-705.5, Gestational diabetes
Abstract

In order to evaluate the performance of a 1-h 75-g oral glucose tolerance test (OGTT) for the diagnosis of gestational diabetes mellitus (GDM), a cohort of 4998 women, 20 years or older, without previous diabetes being treated in prenatal care clinics in Brazil answered a questionnaire and performed a 75-g OGTT including fasting, 1-h and 2-h glucose measurements between their 24th and 28th gestational weeks. Pregnancy outcomes were transcribed from medical registries. GDM was defined according to WHO criteria (fasting: ≥126 mg/dL; 2-h value: ≥140 mg/dL) and macrosomia as a birth weight equal to or higher than 4000 g. Areas under the receiver operator characteristic curve (AUC) were compared and diagnostic properties of various cut-off points were evaluated. The AUCs for the prediction of macrosomia were 0.606 (0.572-0.637) for the 1-h and 0.589 (0.557-0.622) for the 2-h plasma glucose test. Similar predictability was demonstrable regarding combined adverse outcomes: 0.582 (0.559-0.604) for the 1-h test and 0.572 (0.549-0.595) for the 2-h test. When the 1-h glucose test was evaluated against a diagnosis of GDM defined by the 2-h glucose test, the AUC was 0.903 (0.886-0.919). The cut-off point that maximized sensitivity (83%) and specificity (83%) was 141 mg/dL, identifying 21% of the women as positive. A cut-off point of 160 mg/dL, with lower sensitivity (62%), had higher specificity (94%), labeling 8.6% as positive. Detection of GDM can be done with a 1-h 75-g OGTT: the value of 160 mg/dL has the same diagnostic performance as the conventional 2-h value (140 mg/dL). The simplification of the test may improve coverage and timing of the diagnosis of GDM.

16. Sindrome poliglandular autoinmune tipo II en el Hospital Universitario del Caribe, Cartagena, Colombia.

Author

Álvaro José Fortich Revollo, Gustavo Mora García, Adriana Fortich Salvador, Dacia Malambo García, Enrique Carlos Ramos Clason, and Samir Franco García

Subjects
Poliglandular autoinmune, Autoinmunidad, Incidencia, Medicine (General), R5-920
Abstract

El Síndrome Poliglandular Autoinmune es una poliendocrinopatía caracterizada por falla de algunas glándulas endocrinas, así como también en órganos no endocrinos, originada por acciones del sistema inmune sobre tejidos endocrinos. Se han descrito dos grandes grupos y al menos dos o tres variantes de ellos. El Síndrome Poliglandular Autoinmune tipo II es la más común de las inmunoendocrinopatias. Se caracteriza por la presencia de la enfermedad de Addison en combinación con enfermedad tiroidea autoinmune y/o diabetes mellitus tipo I. Se realizo una revisión del tema con bases inmunogenéticas y etiopatológicas. Se presenta una serie de casos. La incidencia acumulada es de 1.2/100.000 habitante. El hallazgo más frecuente fue enfermedad de Addison más Tiroiditis autoinmune, (80 %) y la segunda asociación más frecuente fue tiroiditis con anemia perniciosa (60 %). Es importante resaltar la alta frecuencia de déficit de vitamina B12 en pacientes con severo compromiso neuronal. Pueden transcurrir hasta veinte años desde el diagnóstico de una endocrinopatía y la aparición de otra acompañante. Es deber realizar análisis diagnósticos para evaluar funciones hormonales correlacionadas con una endocrinopatia hasta la senescencia.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results